Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 24921 | 248 | 40.6 | 89% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | VASOHIBIN 1 | Author keyword | 27 | 83% | 6% | 15 |
| 2 | VASOHIBIN | Author keyword | 26 | 87% | 5% | 13 |
| 3 | VASOHIBIN 2 | Author keyword | 21 | 90% | 4% | 9 |
| 4 | MOL PATHOL IMMUNOL CORE | Address | 9 | 83% | 2% | 5 |
| 5 | CHRON KIDNEY DIS CARDIOVASC DIS | Address | 1 | 50% | 1% | 2 |
| 6 | GLOMERULAR VASCULAR POLE | Author keyword | 1 | 50% | 1% | 2 |
| 7 | CHRON KIDNEY DIS PERITONEAL DIALYSIS | Address | 1 | 20% | 2% | 4 |
| 8 | CLIN PNEUMOPHTHISIOL | Address | 1 | 50% | 0% | 1 |
| 9 | DIABET NEPHROPATHY HEMODIALYSIS | Address | 1 | 50% | 0% | 1 |
| 10 | DM NEPHROPATHY | Author keyword | 1 | 50% | 0% | 1 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | VASOHIBIN 1 | 27 | 83% | 6% | 15 | Search VASOHIBIN+1 | Search VASOHIBIN+1 |
| 2 | VASOHIBIN | 26 | 87% | 5% | 13 | Search VASOHIBIN | Search VASOHIBIN |
| 3 | VASOHIBIN 2 | 21 | 90% | 4% | 9 | Search VASOHIBIN+2 | Search VASOHIBIN+2 |
| 4 | GLOMERULAR VASCULAR POLE | 1 | 50% | 1% | 2 | Search GLOMERULAR+VASCULAR+POLE | Search GLOMERULAR+VASCULAR+POLE |
| 5 | DM NEPHROPATHY | 1 | 50% | 0% | 1 | Search DM+NEPHROPATHY | Search DM+NEPHROPATHY |
| 6 | EXTRA VESSELS | 1 | 50% | 0% | 1 | Search EXTRA+VESSELS | Search EXTRA+VESSELS |
| 7 | JUXTAGLOMERULAR ARTERIOLES | 1 | 50% | 0% | 1 | Search JUXTAGLOMERULAR+ARTERIOLES | Search JUXTAGLOMERULAR+ARTERIOLES |
| 8 | KIMMELSTIEL WILSON | 1 | 50% | 0% | 1 | Search KIMMELSTIEL+WILSON | Search KIMMELSTIEL+WILSON |
| 9 | OBESITY MODEL | 1 | 50% | 0% | 1 | Search OBESITY+MODEL | Search OBESITY+MODEL |
| 10 | PANAX NOTOGINOSIDE | 1 | 50% | 0% | 1 | Search PANAX+NOTOGINOSIDE | Search PANAX+NOTOGINOSIDE |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | NEGATIVE FEEDBACK REGULATOR | 32 | 63% | 13% | 32 |
| 2 | PREVENTS GLOMERULAR HYPERTROPHY | 11 | 100% | 2% | 6 |
| 3 | AMELIORATES RENAL ALTERATIONS | 7 | 64% | 3% | 7 |
| 4 | INHIBITOR VASOHIBIN | 3 | 100% | 1% | 3 |
| 5 | VASCULAR POLE | 3 | 50% | 2% | 4 |
| 6 | ANTI VEGF ANTIBODIES | 2 | 67% | 1% | 2 |
| 7 | VASOHIBIN 1 | 2 | 67% | 1% | 2 |
| 8 | ANGIOGENESIS INHIBITOR VASOHIBIN | 1 | 100% | 1% | 2 |
| 9 | ENDOSTATIN PEPTIDE | 1 | 100% | 1% | 2 |
| 10 | VASOHIBIN 1 EXPRESSION | 1 | 100% | 1% | 2 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| The vasohibin family: a novel family for angiogenesis regulation | 2013 | 11 | 38 | 79% |
| Recent Advances in Animal Models of Diabetic Nephropathy | 2014 | 3 | 23 | 52% |
| The vasohibin family: Novel regulators of angiogenesis | 2012 | 7 | 19 | 89% |
| Murine Models of Diabetic Nephropathy | 2012 | 4 | 5 | 100% |
| Mouse models of diabetic nephropathy | 2011 | 43 | 27 | 41% |
| A novel angiogenesis inhibitor vasohibin | 2006 | 0 | 6 | 100% |
| Endothelial dysfunction as a potential contributor in diabetic nephropathy | 2011 | 47 | 107 | 18% |
| New targets for treatment of diabetic nephropathy: what we have learned from animal models | 2013 | 10 | 33 | 24% |
| New Experimental Models of Diabetic Nephropathy in Mice Models of Type 2 Diabetes: Efforts to Replicate Human Nephropathy | 2012 | 14 | 44 | 20% |
| A new mouse model resembling human diabetic nephropathy. uncoupling of VEGF with eNOS as a novel pathogenic mechanism | 2009 | 16 | 34 | 41% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | MOL PATHOL IMMUNOL CORE | 9 | 83% | 2.0% | 5 |
| 2 | CHRON KIDNEY DIS CARDIOVASC DIS | 1 | 50% | 0.8% | 2 |
| 3 | CHRON KIDNEY DIS PERITONEAL DIALYSIS | 1 | 20% | 1.6% | 4 |
| 4 | CLIN PNEUMOPHTHISIOL | 1 | 50% | 0.4% | 1 |
| 5 | DIABET NEPHROPATHY HEMODIALYSIS | 1 | 50% | 0.4% | 1 |
| 6 | FDN DAMICO RICERCA MALATTIE RENALI | 1 | 50% | 0.4% | 1 |
| 7 | HEMATOL ENDOCRINOL DIABETOL | 1 | 50% | 0.4% | 1 |
| 8 | PATHOL MICROBIOL IMMUNOL MED | 1 | 50% | 0.4% | 1 |
| 9 | LEAD GENERAT BIOL | 0 | 20% | 0.8% | 2 |
| 10 | AGING HEALTHCARE | 0 | 33% | 0.4% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000211767 | RUBOXISTAURIN//PENN MOL STUDIES KIDNEY DIS//BEETHAM EYE OPHTHALMOL |
| 2 | 0.0000188449 | HEMODYNAMIC MALADJUSTMENT//FE MG//BOLD MRI |
| 3 | 0.0000140847 | PODOCYTE//NEPHRIN//PODOCIN |
| 4 | 0.0000137388 | DIABETIC GLOMERULOPATHY//NON DIABETIC RENAL DISEASE//STRUCTURAL FUNCTIONAL RELATIONSHIPS |
| 5 | 0.0000117871 | VEGF POLYMORPHISMS//VEGF POLYMORPHISM//RS2010963 |
| 6 | 0.0000116503 | APOL1//APOLIPOPROTEIN L1//APOLIPOPROTEIN L |
| 7 | 0.0000108716 | FLT 1//VEGF RECEPTORS//VEGF165B |
| 8 | 0.0000103586 | HEREDITARY NEPHROTIC MOUSE ICGN//ICGN MOUSE//ICGN MICE |
| 9 | 0.0000085076 | URINARY IGF I//RENAL HYPERTROPHY//SUB MOL ENDOCRINOL |
| 10 | 0.0000076423 | ANGIOPOIETIN 2//TIE2//ANGIOPOIETIN |